Depo-Provera MDL Court Filings & CMOs
Pfizer, the manufacturer of the injectable contraceptive Depo-Provera, is currently facing lawsuits alleging a link between long-term use of the drug (and its generic equivalents) and the development of meningioma — tumors that form on the tissue lining the brain and spinal cord.
As of now, 22 cases have been filed across eight different federal district courts. Plaintiffs argue that Pfizer failed to adequately warn users of the neurological risks associated with Depo-Provera.
A motion has been filed to consolidate these cases into a Multidistrict Litigation (MDL), with a proposed transfer to the Northern District of California. This venue is being considered under the principle of innovator liability, which allows claims to proceed against brand-name manufacturers even when the injured party took a generic version of the drug.
Below are the currently available filings related to this ongoing litigation:
Depo-Provera MDL Case Filings
- 11/26/2024: Memorandum in Support of Motion for Transfer to Create MDL
- 02/23/2025: Case Management Order No. 1 – Initial Case Management Conference & Pilot Case Selection [PDF]
- 03/16/2025: Pretrial Order No. 18 – Plaintiff and Defense Leadership Appointments [PDF]
(More documents will be added as the case develops — bookmark this page to stay up to date.)
Depo-Provera Brain Tumor Lawsuit Information
To learn more about the connection between Depo-Provera and brain tumor risk, visit our Depo-Provera Brain Tumor Lawsuit information page.
For a free consultation with one of our Depo-Provera attorneys, call 202-792-7927.
